[Bamifylline in the therapy of asthmatic syndromes. Efficacy and side effects vs delayed-action theophylline anhydride].

Abstract

Two homogeneous groups of 8 patients suffering from bronchial asthma or chronic obstructive bronchial pneumonia were treated with slow release theophylline anhydride or bamiphylline respectively, both products being given orally twice a day. The results showed that both drugs possess a powerful bronchodilatory action and therefore have a beneficial effect on subjective symptoms. Statistical analysis confirmed the absence of any significant difference between the two xanthine derivatives, both of which were well-tolerated though bamiphylline offered a slight advantage in this respect. In fact there were no side effects at all in the bamiphylline group whereas there was one case of moderate gastric intolerance in the group given theophylline anhydride, though it was not severe enough to warrant suspension of the treatment or reduction of the dose.

• Authors: P Alciato, P A Cantone, D Fico, R Gagliardini, V Petrella
• Journal: Minerva medica (Minerva Med) 1990 Jan-Feb Vol. 81 Issue 1-2 Pg. 93-7 ISSN: 0026-4806 [Print] Italy
• Vernacular Title: La bamifillina nella terapia delle sindromi asmatiche. Efficacia ed effetti collaterali vs teofillina anidra ad azione prolungata.
• PMID: 2314621 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Bronchodilator Agents
• Delayed-Action Preparations
• Theophylline
• bamifylline

Topics

• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Asthma (drug therapy)
• Bronchodilator Agents (administration & dosage, adverse effects, therapeutic use)
• Delayed-Action Preparations
• Female
• Humans
• Lung Diseases, Obstructive (drug therapy)
• Male
• Middle Aged
• Syndrome
• Theophylline (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)